Fang Liang

Fang Liang

Auto-generated profile, based on publicly available information

Fang Liang

Department of Cancer Rehabilitation, The Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou 450007, China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2015 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
FLFang Liang
Fang Liang
JYJunmin Yue
Junmin Yue
JWJunyong Wang
Junyong Wang
LZLijuan Zhang
Lijuan Zhang
RFRui Fan
Rui Fan
QZQingsong Zhang
Qingsong Zhang

17 September 2020 in Experimental Biology and Medicine
Verified
Journal Article
Closed access
PDF file
FLFang Liang
Fang Liang
HZHao Zhang
Hao Zhang
HGHui Gao
Hui Gao
DCDuo Cheng
Duo Cheng
NZNan Zhang
Nan Zhang
LYLu Yin
Lu Yin
As a selective estrogen receptor β agonist, the natural flavonoid liquiritigenin reportedly inhibits invasiveness of breast cancer cells, but its specific role and mechanism remain largely unclear. In this study, cells from the triple negative breast cancer lines MDA-MB-231 and BT549 were incubated with different concentrations of liquiritigenin. The results indicated that low concentrations had no significant cytotoxic effect, whereas high concentrations decreased viability of both MDA-MB-231 and BT549 cells. Liquiritigenin treatment also resulted in increased apoptosis and enhanced Caspase3 activity. After liquiritigenin treatment, we observed decreased invasive and migratory capacities of cells, as well as upregulated E-cadherin and downregulated N-cadherin, vimentin, and MMP9. Interestingly, liquiritigenin increased the mRNA and protein expression of breast cancer 1 (BRCA1). It also increased p21 and growth arrest and DNA-damage-inducible 45 alpha (GADD45A) levels, accompanied by decreased cellular DNA methyltransferase (DNMT) activity and downregulation of DNMT1, DNMT3a, and DNMT3b. These findings suggest that liquiritigenin can inhibit malignant behavior of triple negative breast cancer cells by inhibiting DNMT activity and increasing BRCA1 expression and its transcriptional activity. Liquiritigenin thus may be a promising candidate for the treatment of breast cancer.